Hotgen Biotech released its 2026 interim report, showing total operating revenue of 268 million yuan and a net loss attributable to the parent company of 126 million yuan, a year-on-year widening of 43.3908 million yuan. Net cash flow from operating activities was negative 112 million yuan, a year-on-year decrease of 97.9266 million yuan. The company's asset-liability ratio was 15.44%, gross margin was 65.78%, return on equity was negative 5.17%, and diluted earnings per share was negative 1.36 yuan. The number of shareholders was 10,200, and the top ten shareholders held 49.58% of total share capital.
Beijing Hotgen Biotech Co LtdNet loss widened to 126 million yuan, with negative operating cash flow and negative ROE.
